ARTICLE | Management Tracks
Southwell succeeds Hugh-Jones as CEO of Volastra
Plus: Cellcentric names Celia Economides CFO and CBO, and updates from Mind Medicine, Vectory, Nucleome, Storm and Swiss Rocket
May 28, 2025 12:12 AM UTC
David Southwell became CEO of Volastra Therapeutics Inc., succeeding Charles Hugh-Jones, who has held the role since inception. Southwell was president and CEO of Tscan Therapeutics Inc. (NASDAQ:TCRX) and Inotek Pharmaceuticals Inc. Volastra is developing cancer therapies targeting chromosomal instability.
Cellcentric Ltd. hired Celia Economides as CFO and CBO, following its recent $120 million series C round co-led by RA Capital and Forbion. Economides was interim CEO and CFO of Gritstone Bio Inc. (NASDAQ:GRTS). Cellcentric’s lead program inobrodib, a p300/CBP inhibitor, is in Phase I/IIa trials for hematological and solid tumors...